SCHEMBL4354309

SCHEMBL4354309

O=C(Nc1cc(Cl)cc(Cl)c1O)NC1CCCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.66
NPC1 O15118 6/20 0.59
KMT2A Q03164 5/20 0.57
MEN1 O00255 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.55
HTT P42858 2/20 0.55
EPHX1 P07099 2/20 0.55
ALDH1A1 P00352 2/20 0.55
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
TSHR P16473 3/20 0.54
EPHX2 P34913 5/20 0.53
LMNA P02545 1/20 0.53
CXCR2 P25025 2/20 0.52
KDM4E B2RXH2 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354694 0.83 MEN1 (0.68) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4359527 0.82 RAB9A (0.51) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4353377 0.82 KMT2A (0.54) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4347065 0.81 RAB9A (0.66) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL2751991 0.80 RAB9A (0.66) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4354599 0.80 RAB9A (0.70) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4354614 0.80 RAB9A (0.76) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4348741 0.80 EPHX1 (0.56) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL4349988 0.80 SMN1; SMN2 (0.61) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL2751414 0.79 RAB9A (0.78) RAB9ANPC1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 RAB9A 4228/4885NPC1 815/4885KMT2A 2096/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 RAB9A 4588/4885NPC1 1189/4885KMT2A 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.